CC16 as potential biomarker of epithelial defect in CF

Key Points

• CC16 levels may indicate epithelial defects in cystic fibrosis patients, enhancing clinical assessments.
• Epithelial defects are crucial for understanding disease progression, aiding in better patient management and care.
• Biomarker analysis provides insights into cystic fibrosis, potentially guiding future therapeutic interventions.
• Identifying reliable biomarkers like CC16 may help in monitoring disease status and treatment response in cystic fibrosis.